Published in Lab Business Week, September 16th, 2007
This is also the first prospective, placebo-controlled, study on an adipolytic agent under an active registration program. The study is designed as part of a package aimed at achieving registration of ATX-101 as an approved prescription drug in the U.S., Europe and Asia. The Phase II multi-national, randomized,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week